Maximizing treatment effect

project manager


phd fellow

About the project

MethMax is a clinical trial to investigate whether giving methotrexate subcutaneously, as a syringe under the skin, is more effective than giving tablets. Methotrexate is the most common arthritis medication, and most patients with arthritis start methotrexate shortly after diagnosis. The study is part of the SQUEEZE project, which is a European collaboration that has received more than NOK 100 million for arthritis research from Horizon Europe, the EU's research program.

Who can participate?

Patients over 18 years of age diagnosed with rheumatoid arthritis (arthritis) treated with methotrexate. Recruitment of participants has not yet begun.

Project arrangement

More information on the study is forthcoming.


More information about the SQUEEZE project, which MethMax is part of:

This project has received funding from the European Union's Horizon Europe research and innovation program under grant agreement no. 101095052. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.


All rights reserved © REMEDY; Illustration/portrait images © Nicolas Tourrenc/Diakonhjemmet Hospital